StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

Equities research analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the stock.

Other equities research analysts have also recently issued reports about the company. JMP Securities restated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Tuesday, December 10th. HC Wainwright lifted their price objective on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th.

DBV Technologies Price Performance

Shares of DBV Technologies stock opened at $3.04 on Tuesday. DBV Technologies has a one year low of $2.20 and a one year high of $10.70. The firm has a market capitalization of $62.53 million, a price-to-earnings ratio of -0.68 and a beta of 0.64. The business has a 50-day simple moving average of $3.41 and a 200 day simple moving average of $3.95.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.